Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. Juni 2023 08:00 ET | Quelle: Timber Pharmaceuticals

Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis

- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of Isotretinoin - - Data to be Presented at the Society for...
25. Oktober 2022 08:00 ET | Quelle: Timber Pharmaceuticals

Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis

- Regulatory Milestones Improve Path to Filing a European Marketing Authorization Application -- Company Plans to Submit Additional Application for Orphan Designation in Europe for TMB-001 for the...
15. März 2021 08:30 ET | Quelle: Timber Pharmaceuticals

Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study in Congenital Ichthyosis

- Study is Evaluating TMB-001 (Topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder - Company Awarded Final Tranche of $1.5 Million FDA Orphan Products Clinical Trials...